Martin Gunthorpe

Martin Gunthorpe has more than 25 years of research, drug discovery, and development experience spanning from idea to FDA and EMA approved medicines in the ion channel field.

Prior to Autifony he gained extensive C-level experience as CSO of Endosome Therapeutics (USA), CSO of BioCrea GmbH (Germany), and CEO of a GSK spinout company (UK) and has consulted widely for biotech companies and investors in the life sciences arena.

Previously, he also led preclinical and clinical projects and held senior management positions in the Neurosciences/CNS therapeutic area at GlaxoSmithKline where he worked for over 10 years.

Martin has authored over 40 papers, book chapters and patents relating to ion channel modulators.

Martin obtained an MA in Natural Sciences (Biochemistry) and PhD in Molecular Neuroscience from the University of Cambridge, and is a trained electrophysiologist.